Sarah Elizabeth Gill MD | GCI

Georgia's Online Cancer Information Center

Find A Doctor

Sarah Elizabeth Gill MD
Sarah Elizabeth Gill MD
Nancy N. and J.C. Lewis Cancer & Research Pavilion
https://www.sjchs.org/cancer

Sarah Elizabeth Gill MD

Specialty
Gynecology and Gynecologic Oncology
Trial Cancers
Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian Cancer, Plasma cell neoplasm, Quality of Life, Solid Tumor, Uterine Cancer
Education

Medical School: University of Tennessee College of Medicine, Memphis, TN, USA

Residency: Greenville Hospital System, Greenville, SC, USA

Fellowship: Mayo Clinic, Rochester, MN, USA

Active Clinical Trial Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

225 Candler Drive
Savannah, GA 31405
912-819-5704 (p)
www.sjchs.org

driving directions

Clinical Trials
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Multiple Myeloma

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Non-Hodgkin Lymphoma

A Study to Compare Two Surgical Procedures in Individuals with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type: Ovarian Cancer

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DO-01)
Cancer Type: Ovarian Cancer

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Plasma cell neoplasm

Division of Cancer Prevention NH-DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type: Solid Tumor

Cost Communication and Financial Navigation in Cancer Patients, COSTCOM Trial
Cancer Type: Solid Tumor

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Cancer Type: Unknown Primary

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Cancer Type: Uterine Cancer

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Cancer Type: Uterine Cancer
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.